The Use of Bisphosphonates in Patients With Breast Cancer

Catherine H. Van Poznak, MD


Cancer Control. 2002;9(6) 

In This Article

Long-Term Use of Intravenous Bisphosphonates

To assess for safety and efficacy of long-term intravenous bisphosphonate therapy, Ali et al[25] studied cancer patients receiving pamidronate or zoledronic acid for longer than 2 years. Of the 22 patients identified, 5 were men with multiple myeloma and 17 were women with metastatic breast cancer. The median duration of follow-up was 3.6 years (range 2.2 to 6.0 years). During the first 2 years of treatment with either pamidronate or zoledronic acid, 6 of the 22 patients developed a pathologic fracture or received radiation therapy. Skeletal events that occurred after the first 2 years of bisphosphonate therapy included fractures in 4 of the 22 patients. There was no clinically relevant change in complete blood cell counts, platelet counts, calcium and electrolyte analysis, or kidney function for these patients receiving long-term intravenous bisphosphonate therapy. Long-term use of pamidronate and zoledronic acid appears to be well tolerated.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.